323 related articles for article (PubMed ID: 35002712)
1. An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma.
Xiao Z; Li J; Yu Q; Zhou T; Duan J; Yang Z; Liu C; Xu F
Front Pharmacol; 2021; 12():778294. PubMed ID: 35002712
[No Abstract] [Full Text] [Related]
2. A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.
Li A; Ye B; Lin F; Wang Y; Miao X; Jiang Y
Precis Clin Med; 2022 Jun; 5(2):pbac010. PubMed ID: 35694712
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
4. An endoplasmic reticulum stress-related signature could robustly predict prognosis and closely associate with response to immunotherapy in pancreatic ductal adenocarcinoma.
Liu S; Hu Q; Xie Z; Chen S; Li Y; Quan N; Huang K; Li R; Fang L
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15589-15608. PubMed ID: 37653101
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.
Tan Z; Lei Y; Zhang B; Shi S; Liu J; Yu X; Xu J; Liang C
Front Oncol; 2021; 11():674897. PubMed ID: 34367961
[TBL] [Abstract][Full Text] [Related]
6. Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma.
Song W; He X; Gong P; Yang Y; Huang S; Zeng Y; Wei L; Zhang J
Front Genet; 2021; 12():639246. PubMed ID: 34249078
[No Abstract] [Full Text] [Related]
7. Clinical M2 macrophages-related genes to aid therapy in pancreatic ductal adenocarcinoma.
Xu Q; Chen S; Hu Y; Huang W
Cancer Cell Int; 2021 Oct; 21(1):582. PubMed ID: 34717651
[TBL] [Abstract][Full Text] [Related]
8. Identification of an unfolded protein response-related signature for predicting the prognosis of pancreatic ductal adenocarcinoma.
Fang L; Chen S; Gong H; Xia S; Guan S; Quan N; Li Y; Zeng C; Chen Y; Du J; Liu S
Front Oncol; 2022; 12():1060508. PubMed ID: 36727081
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.
Tian X; Zheng J; Mou W; Lu G; Chen S; Du J; Zheng Y; Chen S; Shen B; Li J; Wang N
Front Pharmacol; 2022; 13():939542. PubMed ID: 35935823
[No Abstract] [Full Text] [Related]
10. Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.
Cai W; Bao W; Chen S; Yang Y; Li Y
Cancer Cell Int; 2021 Dec; 21(1):698. PubMed ID: 34930261
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
12. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer.
Wu M; Li X; Zhang T; Liu Z; Zhao Y
Front Oncol; 2019; 9():996. PubMed ID: 31612115
[No Abstract] [Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia.
Ren M; Feng L; Zong R; Sun H
World J Surg Oncol; 2023 Aug; 21(1):257. PubMed ID: 37605192
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.
Zhu ZG; Chen L; Miao DL; Jin Y; Wu Q
Front Genet; 2022; 13():941389. PubMed ID: 36046234
[No Abstract] [Full Text] [Related]
16. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
[TBL] [Abstract][Full Text] [Related]
17. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment.
Pu N; Chen Q; Gao S; Liu G; Zhu Y; Yin L; Hu H; Wei L; Wu Y; Maeda S; Lou W; Yu J; Wu W
Ann Transl Med; 2019 Nov; 7(22):645. PubMed ID: 31930046
[TBL] [Abstract][Full Text] [Related]
18. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
Front Immunol; 2021; 12():728062. PubMed ID: 34691034
[TBL] [Abstract][Full Text] [Related]
19. Establishment and validation of a prognostic signature for pancreatic ductal adenocarcinoma based on lactate metabolism-related genes.
Huang X; Zhao C; Han Y; Li S
Front Mol Biosci; 2023; 10():1143073. PubMed ID: 37363401
[No Abstract] [Full Text] [Related]
20. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
